Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10344525rdf:typepubmed:Citationlld:pubmed
pubmed-article:10344525lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0019564lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0028351lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0072899lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0079883lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0056831lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0030685lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0086597lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0680255lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0391871lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C1283071lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C1963578lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0051917lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C1519355lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C0251014lld:lifeskim
pubmed-article:10344525lifeskim:mentionsumls-concept:C1627358lld:lifeskim
pubmed-article:10344525pubmed:issue4lld:pubmed
pubmed-article:10344525pubmed:dateCreated1999-7-23lld:pubmed
pubmed-article:10344525pubmed:abstractTextAniracetam, 1-(1,3-benzodioxol-5-yl-carbonyl)piperidine (1-BCP) and cyclothiazide, three compounds considered to enhance cognition through modulation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, were evaluated in the 'kynurenate test', a biochemical assay in which some nootropics have been shown to prevent the antagonism by kynurenic acid of the N-methyl-D-aspartate (NMDA)-evoked [3H]noradrenaline ([3H]NA) release from rat hippocampal slices. Aniracetam attenuated the kynurenate (100 microM) antagonism of the [3H]NA release elicited by 100 microM NMDA with high potency (EC50< or =0.1 microM). Cyclothiazide and 1-BCP were about 10 and 100 times less potent than aniracetam, respectively. The effect of aniracetam persisted in the presence of the AMPA receptor antagonist 6-nitro-7-sulphamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) added at 5 microM, a concentration that did not affect NMDA receptors; in contrast, NBQX reduced the effect of 1-BCP and abolished that of cyclothiazide. The AMPA-evoked release of [3H]NA from hippocampal slices or synaptosomes was enhanced by cyclothiazide, less potently by 1-BCP and weakly by aniracetam. High concentrations of kynurenate (1 mM) antagonized the AMPA-evoked [3H]NA release in slices; this antagonism was attenuated by 1 microM cyclothiazide and reversed to an enhancement of AMPA-evoked [3H]NA release by 10 microM of the drug, but was insensitive to 1-BCP or aniracetam. It is concluded that aniracetam exerts a dual effect on glutamatergic transmission: modulation of NMDA receptor function at nanomolar concentrations, and modulation of AMPA receptors at high micromolar concentrations. As to cyclothiazide and 1-BCP, our data concur with the idea that both compounds largely act through AMPA receptors, although an NMDA component may be involved in the effect of 1-BCP.lld:pubmed
pubmed-article:10344525pubmed:languageenglld:pubmed
pubmed-article:10344525pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:citationSubsetIMlld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10344525pubmed:statusMEDLINElld:pubmed
pubmed-article:10344525pubmed:monthAprlld:pubmed
pubmed-article:10344525pubmed:issn0028-1298lld:pubmed
pubmed-article:10344525pubmed:authorpubmed-author:RaiteriMMlld:pubmed
pubmed-article:10344525pubmed:authorpubmed-author:BonfantiAAlld:pubmed
pubmed-article:10344525pubmed:authorpubmed-author:PittalugaAAlld:pubmed
pubmed-article:10344525pubmed:authorpubmed-author:ArvigoDDlld:pubmed
pubmed-article:10344525pubmed:issnTypePrintlld:pubmed
pubmed-article:10344525pubmed:volume359lld:pubmed
pubmed-article:10344525pubmed:ownerNLMlld:pubmed
pubmed-article:10344525pubmed:authorsCompleteYlld:pubmed
pubmed-article:10344525pubmed:pagination272-9lld:pubmed
pubmed-article:10344525pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:meshHeadingpubmed-meshheading:10344525...lld:pubmed
pubmed-article:10344525pubmed:year1999lld:pubmed
pubmed-article:10344525pubmed:articleTitleAniracetam, 1-BCP and cyclothiazide differentially modulate the function of NMDA and AMPA receptors mediating enhancement of noradrenaline release in rat hippocampal slices.lld:pubmed
pubmed-article:10344525pubmed:affiliationDipartimento di Medicina Sperimentale, Università degli Studi di Genova, Italy.lld:pubmed
pubmed-article:10344525pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10344525pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:10344525pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed